MedTrace Logo

Research of Exenatide for Overweight/Obese PCOS Patients With IGR

NCT03352869 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2019-09-11

No results posted yet for this study

Summary

Compare the therapeutic effects of exenatide, metformin and their combination for 3 months on reproductive and metabolic improvements of overweight/obese PCOS patients with impaired glucose regulation.

Conditions

  • Polycystic Ovary Syndrome
  • Overweight and Obesity
  • Disorder of Glucose Regulation

Interventions

DRUG

Exenatide

Use Exenatide for 3 months to treat PCOS

DRUG

Metformin

Use Metformin for 3 months to treat PCOS

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Tao Tao, MD · RenJi Hospital Department of Endocrinology and Metabolism

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-28
Primary Completion
2018-07-01
Completion
2018-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03352869 on ClinicalTrials.gov